Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» hepatitis C
hepatitis C
Three Upcoming Make-or-Break Biotech Approvals
Seeking Alpha
Sun, 12/19/10 - 11:22 am
Vertex Pharmaceuticals
Telaprevir
Merck
hepatitis C
cystic fibrosis
Human Genome Sciences
Benlysta
lupus
MannKind
Afrezza
inhaled insulin
SciClone shares slide after it dumps failed hep C program
Fierce Biotech
Thu, 12/16/10 - 01:10 pm
SCV-07
SciClone
hepatitis C
Inhibitex: A Biotech Gem in the Enormous Hepatitis C Market
Seeking Alpha
Tue, 11/30/10 - 07:59 am
Inhibitex
hepatitis C
Pharmasset
Vertex Pharmaceuticals
Ligand Pharma says Roche terminates agreement
Reuters
Wed, 11/24/10 - 08:13 am
Roche
Ligand
hepatitis C
Vertex Files for Hep C Drug Approval
TheStreet.com
Tue, 11/23/10 - 10:36 am
hepatitis C
Vertex Pharmaceuticals
FDA
Telaprevir
Medivir Gains as Early Study Shows Drug Kills Hepatitis C Virus
Bloomberg
Thu, 11/18/10 - 08:38 am
Medvir
hepatitis C
Pharmasset Makes Remarkable Recovery on Hepatitis C Franchise
Seeking Alpha
Sun, 11/7/10 - 11:32 am
Pharmasset
hepatitis C
nucleoside polymerase inhibitor
RG7128
Roche
Bad Medicine: When Doctors Tip Off Wall Street
TheStreet.com
Fri, 11/5/10 - 12:19 pm
hedge funds
hepatitis C
Vertex Pharma reports positive results for experimental hepatitis C drug in African Americans
Yahoo/AP
Mon, 11/1/10 - 01:50 pm
hepatitis C
Vertex Pharmaceuticals
Telaprevir
Bristol-Myers Squibb
Merck
JNJ
Medivir Shares Gain After Hepatitis C Drug Test Results Released
Bloomberg
Mon, 11/1/10 - 10:09 am
Medivir
hepatitis C
Vertex, Merck Drugs Help More with Faster Cure for Hepatitis C in Studies
Bloomberg
Sat, 10/30/10 - 12:41 pm
Vertex Pharmaceuticals
Merck
hepatitis C
Telaprevir
Roche
Pegasys
Merck's Investigational Medicine Boceprevir Achieved Significantly Higher SVR Rates In Treatment-Failure and Treatment-Naïve Adult Patients with Chronic Hepatitis C Genotype 1 Compared to Control
Yahoo/BusinessWire
Sat, 10/30/10 - 12:39 pm
Merck
hepatitis C
Boceprevir
Idera Pharmaceuticals Presents Phase 1 Data on IMO-2125 Demonstrating Induction of Broad Antiviral Immune Response in Null-Responder HCV Patients
Yahoo/BusinessWire
Sat, 10/30/10 - 12:23 pm
Idera Pharmaceuticals
IMO-2125
hepatitis C
ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb
Yahoo/PR NewsWire
Sat, 10/30/10 - 12:17 pm
hepatitis C
Anadys
ANA598
Bristol-Myers, Gilead Seek AIDS Cocktail Success in Hepatitis C
Bloomberg
Sat, 10/30/10 - 11:53 am
Bristol-Myers Squibb
Gilead Sciences
HIV
hepatitis C
Vertex Quarter Blemished by Hep C Hiccup
TheStreet.com
Tue, 10/26/10 - 07:19 am
Vertex Pharmaceuticals
earnings
hepatitis C
Telaprevir
Bristol-Myers gets drug approvals, awaits more
Yahoo/AP
Sat, 10/23/10 - 12:42 pm
Bristol-Myers Squibb
pegylated interferon lambda
hepatitis C
Sprycel
chronic myeloid leukemia
Onglyza
InterMune sells Hep C drug rights to Roche
Marketwatch
Wed, 10/6/10 - 06:54 pm
hepatitis C
InterMune
Roche
danoprevir
Novartis Discontinues Two Drugs
TheStreet.com
Tue, 10/5/10 - 07:03 am
Novartis
Human Genome Sciences
hepatitis C
antifungals
Mycograb
Vertex Edges Merck In First Round of Hepatitis C Fight
Forbes
Mon, 10/4/10 - 05:21 pm
Merck
Vertex Pharmaceuticals
hepatitis C
Telaprevir
protease inhibitors
Pages
« first
‹ previous
…
41
42
43
44
45
46
47
48
49
next ›
last »